Patents by Inventor Nathalie Vergnolle

Nathalie Vergnolle has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Publication number: 20210040231
    Abstract: The invention is in the field of therapy of gut inflammatory diseases such as Inflammatory Bowel Diseases (IBD) or Irritable Bowel Syndrome (IBS) including Gluten hypersensitivity. The inventors showed that ELA2A secreted by epithelial cells in the extracellular space is over-expressed in IBD conditions degrading tight junction proteins and controlling cytokines expression. Overexpression of ELA2A conferred a pro-inflammatory phenotype both in cell expression systems and in vivo in animal model of IBD. The inventors also showed that ELA2 over-expressing intestinal epithelial cells increase the release of CXCL8 protein compared to control cells. The increased CXCL-8 protein release observed in cells overexpressing ELA2A is inhibited by ELAFIN addition to the culture, in a dose-dependent manner. In particular, the invention relates to inhibitors of Elastase ELA2A, for use in the treatment of Inflammatory Bowel Diseases, such as Crohn's Disease, Ulcerative Colitis, Celiac disease, and Pouchitis.
    Type: Application
    Filed: September 22, 2020
    Publication date: February 11, 2021
    Inventors: Nathalie VERGNOLLE, Corinne ROLLAND, Céline DERAISON-MANUEL
  • Patent number: 10829563
    Abstract: The invention is in the field of therapy of gut inflammatory diseases such as Inflammatory Bowel Diseases (IBD) or Irritable Bowel Syndrome (IBS) including Gluten hypersensitivity. The inventors showed that ELA2A secreted by epithelial cells in the extracellular space is over-expressed in IBD conditions degrading tight junction proteins and controlling cytokines expression. Overexpression of ELA2A conferred a pro-inflammatory phenotype both in cell expression systems and in vivo in animal model of IBD. The inventors also showed that ELA2 over-expressing intestinal epithelial cells increase the release of CXCL8 protein compared to control cells. The increased CXCL-8 protein release observed in cells overexpressing ELA2A is inhibited by ELAFIN addition to the culture, in a dose-dependent manner. In particular, the invention relates to inhibitors of Elastase ELA2A, for use in the treatment of Inflammatory Bowel Diseases, such as Crohn's Disease, Ulcerative Colitis, Celiac disease, and Pouchitis.
    Type: Grant
    Filed: June 16, 2017
    Date of Patent: November 10, 2020
    Assignees: INSERM (INSTITUTE NATIONAL DE LA SANTÉ ET DE LA RECHERCHE MÉDICALE), Université Toulouse III—Paul Sabatier, CENTRE NATIONAL DE LA RECHERCHE SCIENTIFIQUE (CNRS)
    Inventors: Nathalie Vergnolle, Corinne Rolland, Céline Deraison-Manuel
  • Publication number: 20190177433
    Abstract: The invention is in the field of therapy of gut inflammatory diseases such as Inflammatory Bowel Diseases (IBD) or Irritable Bowel Syndrome (IBS) including Gluten hypersensitivity. The inventors showed that ELA2A secreted by epithelial cells in the extracellular space is over-expressed in IBD conditions degrading tight junction proteins and controlling cytokines expression. Overexpression of ELA2A conferred a pro-inflammatory phenotype both in cell expression systems and in vivo in animal model of IBD. The inventors also showed that ELA2 over-expressing intestinal epithelial cells increase the release of CXCL8 protein compared to control cells. The increased CXCL-8 protein release observed in cells overexpressing ELA2A is inhibited by ELAFIN addition to the culture, in a dose-dependent manner. In particular, the invention relates to inhibitors of Elastase ELA2A, for use in the treatment of Inflammatory Bowel Diseases, such as Crohn's Disease, Ulcerative Colitis, Celiac disease, and Pouchitis.
    Type: Application
    Filed: June 16, 2017
    Publication date: June 13, 2019
    Inventors: Nathalie VERGNOLLE, Corinne ROLLAND, Céline DERAISON-MANUEL
  • Patent number: 9688742
    Abstract: The present invention relates to the general field of therapy of Inflammatory Bowel Disease (IBD) and/or Irritable Bowel Syndrome (IBS). Thus, the invention relates to a molecule selected from the trappin-2 protein or an active fraction thereof, a member of the WAP family proteins or an active fraction thereof or a member of the Serpin family proteins or an active fraction thereof for the treatment of Irritable Bowel Syndrome (IBS). The invention also relates to a recombinant food-grade bacterium comprising a gene selected from a gene coding for the trappin-2 protein or an active fraction thereof, a gene coding for a member of the WAP family proteins or an active fraction thereof, or a gene coding for a member of the Serpin family proteins or an active fraction thereof.
    Type: Grant
    Filed: September 18, 2014
    Date of Patent: June 27, 2017
    Assignees: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE (INSERM), INSTITUT NATIONAL DE LA RECHERCHE AGRONOMIQUE (INRA), UNIVERSITE PARIS DIDEROT—Paris 7
    Inventors: Nathalie Vergnolle, Jean-Michel Sallenave, Philippe Langella, Luis Bermudez-Humaran
  • Patent number: 9125861
    Abstract: Methods and compositions (such as pharmaceutical compositions) for treating influenza virus type A infections in human subjects include PAR2 agonists being administered to the subject. The PAR2 agonists include small organic molecules, antibodies, and aptamers. In addition, the PAR2 agonist may be a PAR2 activating peptide. Exemplary PAR2 activating peptides include SLIGRL (SEQ ID NO: 1) and SLIGKV (SEQ ID NO: 2).
    Type: Grant
    Filed: May 3, 2010
    Date of Patent: September 8, 2015
    Assignees: Institut National de la Sante et de la Recherche Medicale (INSERM), Institut National de la Recherche Agronomique (INRA)
    Inventors: Nathalie Vergnolle, Beatrice Riteau
  • Publication number: 20150073125
    Abstract: The present invention relates to the general field of therapy of Inflammatory Bowel Disease (IBD) and/or Irritable Bowel Syndrome (IBS). Thus, the invention relates to a molecule selected from the trappin-2 protein or an active fraction thereof, a member of the WAP family proteins or an active fraction thereof or a member of the Serpin family proteins or an active fraction thereof for the treatment of Irritable Bowel Syndrome (IBS). The invention also relates to a recombinant food-grade bacterium comprising a gene selected from a gene coding for the trappin-2 protein or an active fraction thereof, a gene coding for a member of the WAP family proteins or an active fraction thereof, or a gene coding for a member of the Serpin family proteins or an active fraction thereof.
    Type: Application
    Filed: September 18, 2014
    Publication date: March 12, 2015
    Inventors: Nathalie Vergnolle, Jean-Michel Sallenave, Philippe Langella, Luis Bermudez-Humaran
  • Publication number: 20130344033
    Abstract: The present invention relates to the general field of therapy of Inflammatory Bowel Disease (IBD) and/or Irritable Bowel Syndrome (IBS). Thus, the invention relates to a molecule selected from the trappin-2 protein or an active fraction thereof, a member of the WAP family proteins or an active fraction thereof or a member of the Serpin family proteins or an active fraction thereof for the treatment of Irritable Bowel Syndrome (IBS). The invention also relates to a recombinant food-grade bacterium comprising a gene selected from a gene coding for the trappin-2 protein or an active fraction thereof, a gene coding for a member of the WAP family proteins or an active fraction thereof, or a gene coding for a member of the Serpin family proteins or an active fraction thereof.
    Type: Application
    Filed: May 21, 2013
    Publication date: December 26, 2013
    Applicants: INSTITUT NATIONAL DE LA SANTE ET DE LA RECHERCHE MEDICALE, UNIVERSITE PARIS DIDEROT - PARIS 7, INSTITUT NATIONAL DE LA RECHERCHE AGRONOMIQUE (INRA)
    Inventors: Nathalie Vergnolle, Jean-Michel Sallenave, Philippe Langella, Luis Bermudez-Humaran
  • Publication number: 20120195859
    Abstract: The present invention relates to the general field of therapy of Inflammatory Bowel Disease (IBD) and/or Irritable Bowel Syndrome (IBS). Thus, the invention relates to a molecule selected from the trappin-2 protein or an active fraction thereof, a member of the WAP family proteins or an active fraction thereof or a member of the Serpin family proteins or an active fraction thereof for the treatment of Irritable Bowel Syndrome (IBS). The invention also relates to a recombinant food-grade bacterium comprising a gene selected from a gene coding for the trappin-2 protein or an active fraction thereof, a gene coding for a member of the WAP family proteins or an active fraction thereof, or a gene coding for a member of the Serpin family proteins or an active fraction thereof.
    Type: Application
    Filed: January 24, 2012
    Publication date: August 2, 2012
    Inventors: Nathalie VERGNOLLE, Jean-Michel Sallenave, Philippe Langella, Luis Bermudez-Humaran
  • Publication number: 20120058127
    Abstract: The present invention provides methods and compositions (such as pharmaceutical compositions) for treating or preventing influenza virus type A infections. More particularly, the invention relates to a PAR2 agonist for use in the treatment or prevention of an influenza virus type A infection.
    Type: Application
    Filed: May 3, 2010
    Publication date: March 8, 2012
    Inventors: Nathalie Vergnolle, Béatrice Riteau